The DiaSorin solution
DiaSorin offers global blood screening and diagnostic solutions for both viral hepatitis and retroviruses detection.
The available assays include both ELISA format, with the benefit of the Murex brand, and the fully automated CLIA solution on the LIAISON® family systems.
DiaSorin hepatitis and retroviruses solution ensures fast, accurate detection and screening and the highquality diagnostic results also support treatment decisions and clinical follow-up of infected patients.
DiaSorin improves the prevention and treatment of both hepatitis and retroviruses epidemics by optimizing first-line virological evaluation with a complete, fully automated CLIA diagnostic panel.
Easy, automated and efficient
- Accurately differentiate hepatitis and retroviruses infections with the widest portfolio of chemiluminescence immunoassays (CLIA)
- Improve laboratory efficiency and workflows by implementing a comprehensive hepatitis and retroviruses solution on the fully-automated LIAISON® XL platform
- Optimize transfusion-transmissible infection detection thanks to blood donor screening for HBV, HCV, HIV, HTLV, Treponema and Chagas
- Safely select donors with the widest validated panel for screening post-mortem organs, tissues and cells, including HBV, HCV, HDV, HEV, HIV and HTLV
- Consolidate the fully-automated CLIA hepatitis and retroviruses panel within our comprehensive portfolio for infectious disease diagnosis
The LIAISON® XL Murex HBsAg Quant assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.
The LIAISON® XL MUREX HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of Hepatitis B surface Antigen (HBsAg) in human serum and plasma samples included specimens collected post-mortem (non-heart beating). The assay is intended as an aid in the diagnosis of HBV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for blood and hemocomponents donors as well as for organ, tissue and cells post-mortem donors. The test has to be performed on the LIAISON® XL analyzer only.
The LIAISON® XL MUREX HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of Hepatitis B surface Antigen (HBsAg) in human serum and plasma samples included specimens collected post-mortem (non-heart beating). The assay is intended as an aid in the diagnosis of HBV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for blood and hemocomponents donors as well as for organ, tissue and cells post-mortem donors. The test has to be performed on the LIAISON® XL Analyzer only.
The LIAISON® HBsAg assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of hepatitis B surface antigen (HBsAg) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer only.
The HBsAg Confirmatory Test is an in vitro neutralization assay for confirmation of the presence of hepatitis B surface antigen (HBsAg) in human serum and plasma samples found repeatedly reactive for HBsAg by LIAISON® XL Murex HBsAg Quant or LIAISON® HBsAg.
The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® XL Anti-HBs II assay uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Anti-HBc assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of total antobodies to hepatitis B core antigen (anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® HBc IgM assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulim to hepatitis B core antigen (IgM anti-HBc) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® HBeAg assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of e antigen of hepatitis B virus (HBeAg) in human serum or plasma samples. HBeAg quantification may allow follow up of replicative activity/response to treatment (e.g. interferon) (20). The test has to be performed on the LIAISON® analyzer family.
The LIAISON® Anti-HBe assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis B a antigen (anti-Bbe) in human serum or plasma samples. The test had to be perfomed on the LIAISON® analyzer family.
The LIAISON® Anti-HAV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of total antibodies to hepatitis A virus (anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® HAV IgM assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of IgM immunoglobulin to hepatitis A virus (IgM anti-HAV) in human serum or plasma samples. The test has to be performed on the LIAISON® analyzer family.
The LIAISON® XL Murex HCV Ab assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to hepatitis C virus (anti-HCV) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.
The LIAISON® XL Murex HIV Ab / Ag assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples. The test has to be performed on the LIAISON® XL analyzers only.
The LIAISON® XL Murex HIV Ab / Ag HT assay uses chemiluminescence immunoassay (CLIA) technology for the combined qualitative determination of p24 antigen of human immunodeficiency virus type 1 (HIV-1) and specific antibodies to both human immunodeficiency virus type 1 (group M and group O) and/or human immunodeficiency virus type 2 (HIV-2) in human serum or plasma samples.
The LIAISON® XL Murex HIV Ab / Ag HT assay is intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection and as a screening test for donated blood and plasma.
The test has to be performed on the LIAISON® XL Analyzer only.
The LIAISON® XL Murex recHTLV-I/II assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative determination of specific antibodies to Human T-cell Lymphotropic Virus (HTLV) type I and type II (anti-HTLV-I and anti-HTLV-II) in human serum or plasma samples.
The test has to be performed on the LIAISON® XL analyzer only.
The LIAISON® XL Murex Anti-HDV assay uses chemiluminescence immunoassay (CLIA) technology for the qualitative detection of total antibodies to hepatitis D virus in human serum and plasma samples. The assay results, in conjunction with other laboratory results and clinical information, are intended to be used as an aid in the diagnosis of HDV infection and as a screening test for organ and tissue donors.
Visit also http://hdv.diasorin.com/
The LIAISON® Murex Anti-HEV IgG assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of IgG antibodies to hepatitis E virus (Anti-HEV IgG) in human serum and plasma samples, including specimens collected post-mortem (non-heart beating).
The assay is intended as an aid in the diagnosis of HEV infection in individuals with or without symptoms of hepatitis and to evaluate the presence and the amount of Anti-HEV IgG. It is also intended as a screening test for post-mortem organ, tissue, and cell donors.
The assay has to be performed on the LIAISON® Analyzer family
The LIAISON® Murex Anti-HEV IgM assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of IgM antibodies to hepatitis E virus (Anti-HEV IgM) in human serum and plasma samples, including specimens collected post-mortem (non-heart beating).
The assay is intended as an aid in the diagnosis of HEV infection in individuals with or without symptoms of hepatitis. It is also intended as a screening test for post-mortem organ, tissue, and cells donors.
The assay has to be performed on the LIAISON® Analyzer family.
Enzyme immunoassay for the detection of hepatitis B surface antigen in human serum or plasma.
For the confirmation of the presence of hepatitis B surface antigen in human serum and plasma samples. To be used on serum or plasma samples found to be reactive in the Murex HBsAg Version 3 (9F80) assay.
Enzyme immunoassay for the detection of antibodies to hepatitis B core antigen (anti-HBc) in human serum or plasma.
An enzyme immunoassay for the detection of antibodies to hepatitis C virus (HCV) in human serum or plasma.
Immunoassay for the simultaneous detection of hepatitis C (HCV) core antigen and anti-HCV antibodies in human serum or plasma.
Enzyme immunoassay for improved detection of seroconversion to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and detection of anti-HIV-2 antibodies in human serum or plasma.
Enzyme immunoassay for the detection of antibodies to human immunodeficiency virus types 1 (HIV-1, HIV-1 group O) and 2 (HIV-2) in human serum or plasma.
A qualitative enzyme immunoassay for the detection of antibodies against human T-lymphotropic virus types I and II (HTLV-I and HTLV-II) in human serum and plasma.
Enzyme immunoassay for the detection of antibodies against Treponema pallidum in human serum and plasma.
